The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
LettersFull Access

Dementia and Hormone Use

To the Editor: In the January issue, Baqar Husaini, Ph.D, and his colleagues (1) describe racial differences in the incidence of dementia and the costs of treating it. In their discussion, they hypothesize that relatively less common use of "hormone replacement therapy" might account for the overrepresentation of African Americans and women with lower incomes among people afflicted with dementia.

Using similar reasoning, we believed until recently that exogenous hormones administered to peri- and postmenopausal women would prevent cardiovascular disease. Recent findings to the contrary underscore the fact that hormone users are a self-selected population whose relatively better health derives from factors more subtle than income, education, or race. Observational studies are useful for identifying areas of more systematic research but not sufficient for initiating preventive treatment of the general population.

Dr. Stotland is professor in the departments of psychiatry and obstetrics and gynecology at Rush Medical College in Chicago.

Reference

1. Husaini BA, Sherkat DE, Moonis M, et al: Racial differences in the diagnosis of dementia and in its effects on the use and costs of health care services. Psychiatric Services 54:92-96, 2003LinkGoogle Scholar